PRESS RELEASE : Invitation to MorphoSys' First Quarter Results Conference Call on May 6, 2021

DGAP-News: MorphoSys AG / Key word(s): Quarter Results 
Invitation to MorphoSys' First Quarter Results Conference Call on May 6, 2021 
2021-04-28 / 22:00 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Conference Call Alert 
Planegg/Munich, Germany, April 28, 2021 
Invitation to MorphoSys' First Quarter Results Conference Call on May 6, 2021 
 
MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR), a commercial-stage biopharmaceutical 
company and a leader in antibody, protein and peptide technologies, will publish its results for the first quarter of 
2021 on May 5, 2021 at 10:00pm CEST (4:00pm EDT). 
MorphoSys' Management Board will host a conference call and webcast on May 6, 2021 at 2:00pm CEST (8:00am EDT) to 
present the first quarter and first 3-month financial results 2021 and provide an outlook for 2021. 
The conference call will start with a presentation by the Management Board followed by a Q&A session. Following Board 
Members will be on the call: 
- Jean-Paul Kress, M.D., Chief Executive Officer 
- Sung Lee, Chief Financial Officer 
- Roland Wandeler, Ph.D., Chief Operating Officer 
- Malte Peters, M.D., Chief Research & Development Officer 
A live webcast and slides will be made available at the Media and Investors section under Conferences on MorphoSys' 
website, http://www.morphosys.com. 
Dial-in number for the conference call (2:00pm CEST, 8:00am EDT): 
Germany: [phone] 
For UK residents: [phone] 
For US residents: [phone] 
(all numbers reachable from any geography) 
Participant PIN: 30606690# 
Please dial in 10 minutes before the beginning of the conference. 
A replay of the conference will also be available at the corporate website following the live event. 
About MorphoSys 
MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development and commercialization 
of innovative therapies for patients suffering from cancer and autoimmune diseases. Based on its leading expertise in 
antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the 
development of more than 100 product candidates, of which more than 25 are currently in clinical development. In 2017, 
Tremfya^(R), developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc., for the treatment 
of plaque psoriasis, became the first drug based on MorphoSys' antibody technology to receive regulatory approval. In 
July 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval of the company's proprietary 
product Monjuvi^(R) (tafasitamab-cxix) in combination with lenalidomide in patients with a certain type of lymphoma. 
Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., 
has more than 600 employees. More information at www.morphosys.com or www.morphosys-us.com. 
Monjuvi^(R) is a registered trademark of MorphoSys AG. 
Tremfya^(R) is a registered trademark of Janssen Biotech, Inc. 
MorphoSys Forward-Looking Statements 
This communication contains certain forward-looking statements concerning the MorphoSys group of companies, including 
the expectations regarding Monjuvi's ability to treat patients with relapsed or refractory diffuse large B-cell 
lymphoma, the further clinical development of tafasitamab including ongoing confirmatory trials, additional 
interactions with regulatory authorities and expectations regarding future regulatory filings and possible additional 
approvals for tafasitamab as well as the commercial performance of Monjuvi. The words "anticipate," "believe," 
"estimate," "expect," "intend," "may," "plan," "predict," "project," "would," "could," "potential," "possible," "hope" 
and similar expressions are intended to identify forward-looking statements, although not all forward-looking 
statements contain these identifying words. The forward-looking statements contained herein represent the judgment of 
MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the 
actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be 
materially different from any historic or future results, financial conditions and liquidity, performance or 
achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, 
performance, financial condition and liquidity, and the development of the industry in which it operates are consistent 
with such forward-looking statements, they may not be predictive of results or developments in future periods. Among 
the factors that may result in differences are MorphoSys' expectations regarding risks and uncertainties related to the 
impact of the COVID-19 pandemic to MorphoSys' business, operations, strategy, goals and anticipated milestones, 
including its ongoing and planned research activities, ability to conduct ongoing and planned clinical trials, clinical 
supply of current or future drug candidates, commercial supply of current or future approved products, and launching, 
marketing and selling current or future approved products, the global collaboration and license agreement for 
tafasitamab, the further clinical development of tafasitamab, including ongoing confirmatory trials, and MorphoSys' 
ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials, 
additional interactions with regulatory authorities and expectations regarding future regulatory filings and possible 
additional approvals for tafasitamab as well as the commercial performance of Monjuvi, MorphoSys' reliance on 
collaborations with third parties, estimating the commercial potential of its development programs and other risks 
indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the U.S. 
Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on 
such forward-looking statements. These forward-looking statements speak only as of the date of publication of this 
document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document 
to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on 
which any such statement is based or that may affect the likelihood that actual results will differ from those set 
forth in the forward-looking statements, unless specifically required by law or regulation. 
For more information, please contact: 
 
Media Contacts:               Investor Contacts: 
Thomas Biegi                  Dr. Julia Neugebauer 
Vice President                Senior Director 
Tel.: +49 (0)89 / 89927 26079 Tel: +49 (0)89 / 899 27 179 
[e-mail]    [e-mail] 
Jeanette Bressi               Myles Clouston 
Director, US Communications   Senior Director 
Tel: [phone]          Tel: [phone] 
[e-mail] [e-mail] ----------------------------------------------------------------------------------------------------------------------- 

2021-04-28 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de -----------------------------------------------------------------------------------------------------------------------

Language:     English 
Company:      MorphoSys AG 
              Semmelweisstr. 7 
              82152 Planegg 
              Germany 
Phone:        [phone] 
Fax:          [phone] 
E-mail:       [e-mail] 
Internet:     www.morphosys.com 
ISIN:         DE0006632003 
WKN:          663200 
Indices:      MDAX, TecDAX 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 
              Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq 
EQS News ID:  1189907 
 
End of News   DGAP News Service 
=------------ 

1189907 2021-04-28

 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1189907&application_name=news

(END) Dow Jones Newswires

April 28, 2021 16:00 ET (20:00 GMT)